Healthcare Industry News: US Biologic
News Release - October 16, 2006
Pegasus Biologics Enters Wound Care Market With FDA Clearance for DermADAPT(TM) BiomatrixIRVINE, Calif.--(HSMN NewsFeed)--Pegasus Biologics, Inc., developers of advanced biologic scaffolds, announced today that they have received FDA clearance for the DermADAPT(TM) Biomatrix Wound Dressing, a highly organized collagen matrix intended for the local management of moderate to heavy exuding wounds. The Company will initially focus on the enormous opportunity within the diabetic foot ulcer market.
Al Weinstein, Executive VP, Sales and Marketing added, "We are grateful for the acceptance we have had of the OrthADAPT Bioimplant clinically, and we believe physicians will be extremely pleased with advantages offered by the DermADAPT Biomatrix. Unlike some other collagen-based wound dressings, it is strong and stable, maintaining an ideal environment for wound healing. At the same time, it is thin and pliable, and conforms well to the wound bed."
The DermADAPT Biomatrix and the OrthADAPT Bioimplants utilize Pegasus Biologics' proprietary licensed technologies, UltiFIX® and UltiSTER(TM), that stabilize and sterilize biological tissues using safe and nondestructive methods, resulting in decellularized collagen matrices that are extremely biocompatible and strong. Studies have indicated that PegasUS Biologic scaffolds are resistant to enzymes for controlled biodegradation and subsequent remodeling in the patient.
Pegasus Biologics, Inc.
Pegasus Biologics, Inc. (Irvine, CA) is a privately held company focused on the development and commercialization of next generation biologics utilizing the Company's unique and patented technologies. Additional information on the Company can be found at www.pegasusbio.com.
Source: Pegasus Biologics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.